# ValiRx Plc Clinical efficacy of VAL401

- Link: https://www.directorstalkinterviews.com/valirx-plc-clinical-efficacy-val401/412742407
- Published: 2017-12-18T13:24:12+00:00
- Author: Giles Arbor

**[⌊Hardman & Co Report Report Downloads⌉⌊Hardman & Co Report Report Downloads⌉[ValiRx Plc**(
LON:VAL) is a clinical-stage biopharmaceutical company focused on the development
of therapeutics for the treatment of cancer, associated biomarkers and companion
diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase
I/II) – a peptide for advanced prostate cancer and potentially other hormone- induced
indications; and VAL401 (Phase II) – a reformulation of risperidone, in trials for
lung cancer. Early clinical analysis of its Phase II trial with VAL 401 has been
released, meeting its primary endpoint by providing a statistically significant 
improvement in the overall survival rate. Further data will be revealed in due course.

**Strategy:** The company operates as a virtual business, out-sourcing most of its
activities. The core strategy is to develop its therapeutic assets through the clinical
pathway and seek a partner/licensing deal to complete the development programme 
and regulatory submissions to commercialise the products.

**Overall survival data:** The newly published data on non-small cell lung cancer
patients that exhausted all possible existing therapies, provide statistically significant
improvement in the overall survival rate. Further analyses in quality of life and
characterising the best responders will be revealed in due course.

**Valuation:** This data provides an important value inflection point which was 
not reflected previously in the share price. The market has reacted promptly to 
this news, with the share price jumping from 1p at the end of November (capital 
increase) to 7.73p – a near eight-fold increase!

**Next steps:** Safety and tolerability of VAL401 has been confirmed in late stage
patients affected by non-small cell lung cancer. The study has provided also the
dosing level that will be used in subsequent trials. Full data analysis is underway,
and the final read-out of the study is expected in the near future.

**Investment summary:** The market has failed to recognise the potential of ValiRx
Plc, fretting more about the need for more capital to advance its clinical programmes
that taking a rational view of the likely success of its clinical candidates. Given
the clinical progress seen to date, the company will be attracting the attention
of potential commercial partners and/or institutional investors in order to achieve
the true value of its assets.

Share on: